Role of of Montilukaste with or without Desloratidin in treatment of Bronchial Asthma

Abstract

The role of leukotriens antagonist alone and with the new generation H1 antihistaminics is not well elucidated. This study has been designed to evaluate the role of montilukast with and without desloratidine in the treatment of mild to moderate severity bronchial asthma. This is a double blind placebo control clinical trial which has been conducted on 150 patients with mild to moderate bronchial asthma in the period between July 2011 to January 2012 in Tikrit General Hospital and Private Clinic. The patients were divided into 3 groups, first group received montilukast alone, the second group received montilukast plus desloratidine and the third group received placebo tablet. Forced expiratory volume in first second (FEV1), Peak expiratory flow rate (PEFR), and Asthmatic Symptom Score were measured before and after the treatment period of three months. There was a significant improvements in all parameters in the montilukast group (P≤ 0.01). The combination of montilukast with desloratidIne resulted in a highly significant improvement in all parameters (P≤ 0.001). From this study we conclude that montilukast is a useful drug in the armamentarium against asthma, however the addition of desloratidine appears to have synergistic action in patients with mild to moderate bronchial asthma